Merck & Co’s Ervebo (Ebola Zaire Vaccine, Live) Receives Approval in Four African Countries

 Merck & Co’s Ervebo (Ebola Zaire Vaccine, Live) Receives Approval in Four African Countries

Merck & Co’s Ervebo (Ebola Zaire Vaccine, Live) Receives Approval in Four African Countries

Shots:

  • The Ervebo has received approval in DRC, Burundi, Ghana, and Zambia, following the implementation of the WHO’s Roadmap for introduction & roll‐out of Merck’s rVSV-ZEBOV Ebola virus vaccine in African countries
  •  The 4 countries have licensed an Ebola vaccine within 90 days after WHO prequalification with its anticipated registration in other African countries in the coming wks. Merck in collaboration with the US govt. WHO, UNICEF, and Gavi will support public health preparedness and response efforts against Zaire ebolavirus disease
  • Additionally, Merck will initiate the manufacturing of licensed dosing with its anticipated availability in Q3’20. Ervebo is indicated for the prevention of disease caused by Zaire ebolavirus in patients aged ≥18yrs.

Click here ­to­ read full press release/ article | Ref: Merck | Image: Merck

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post